Ribavirin Dose Optimization for the Treatment of Hepatitis C
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a
category of patients for whom there is currently no worthwhile therapeutic alternative.
Several studies have shown that there is a relation between plasma ribavirin concentrations
and treatment response. Adequate ribavirin plasma concentrations, especially during the first
12 weeks of treatment, should be associated with a better chance of response to the
treatment.
The strategy for this study will be to use a loading dose of ribavirin before beginning the
treatment with peg-interferon, thereby allowing for optimal ribavirin concentrations to be
reached, and possibly improving the effectiveness of the treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators:
Centre de Recherche du Centre Hospitalier de l'Université de Montréal Hoffmann-La Roche